Z1TS34.SA Zoetis Inc.
- Market cap
- BRL 208B
- P/E
- 15.6x
- P/B
- 11.03x
- ROE
- 82.1%
- Dividend yield
- 1.54%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is Z1TS34.SA undervalued?
Graham numberZ1TS34.SA trades 176.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zoetis Inc. fundamental analysis
No fundamental analysis for Zoetis Inc. yet.
Zoetis Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also …
Full company profileZoetis Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zoetis Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 5.83B | 6.26B | 6.68B | 7.78B | 8.08B | 8.54B | 9.26B | 9.47B | 9.46B |
| Gross Profit | 3.91B | 4.27B | 4.62B | 5.47B | 5.63B | 6.02B | 6.54B | 6.81B | 6.83B |
| Operating Income | 1.88B | 2.02B | 2.27B | 2.80B | 2.66B | 2.94B | 3.13B | 3.36B | 3.64B |
| EBITDA | 2.20B | 2.44B | 2.67B | 3.16B | 3.34B | 3.67B | 3.86B | 4.07B | 3.97B |
| Net Income | 1.43B | 1.50B | 1.64B | 2.04B | 2.11B | 2.34B | 2.49B | 2.67B | 2.58B |
| EPS | 2.98 | 3.15 | 3.45 | 4.31 | 4.56 | 5.11 | 5.54 | 6.29 | 6.24 |
| Balance Sheet | |||||||||
| Total Assets | 10.8B | 11.5B | 13.6B | 13.9B | 14.9B | 14.3B | 14.2B | 15.5B | 15.1B |
| Total Liabilities | 8.59B | 8.84B | 9.84B | 9.36B | 10.5B | 9.30B | 9.47B | 12.1B | 11.9B |
| Shareholders' Equity | 2.19B | 2.71B | 3.77B | 4.54B | 4.41B | 5.00B | 4.77B | 3.33B | 3.15B |
| Cash & Short-term Investments | 1.60B | 1.93B | 3.60B | 3.48B | 3.58B | 2.04B | 1.99B | 2.31B | 1.47B |
| Cash Flow | |||||||||
| Operating Cash Flow | 1.79B | 1.80B | 2.13B | 2.21B | 1.91B | 2.35B | 2.95B | 2.90B | 2.11B |
| Capital Expenditure | 338M | 460M | 453M | 477M | 586M | 732M | 655M | 621M | 454M |
| Free Cash Flow | 1.45B | 1.34B | 1.67B | 1.74B | 1.33B | 1.62B | 2.30B | 2.28B | 1.66B |
| Ratios | |||||||||
| ROE | 65.4% | 55.4% | 43.5% | 44.8% | 48.0% | 46.9% | 52.1% | 80.2% | 82.1% |
| ROA | 13.3% | 13.0% | 12.0% | 14.7% | 14.2% | 16.4% | 17.5% | 17.3% | 17.1% |
| Net Profit Margin | 24.5% | 24.0% | 24.5% | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% | 27.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zoetis Inc. dividends
- Dividend yield
- 1.54%
- Forward dividend
- 0.46 BRL
- Payout ratio
- 33.3%
- Ex-dividend date
- Oct 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 889M | 2.09 | 33.3% |
| 2024 | USD 786M | 1.75 | 31.6% |
| 2023 | USD 692M | 1.51 | 29.5% |
| 2022 | USD 611M | 1.32 | 28.9% |
| 2021 | USD 474M | 1.00 | 23.3% |
| 2020 | USD 380M | 0.80 | 23.2% |
| 2019 | BRL 314M | 0.66 | 20.9% |
| 2018 | BRL 243M | 0.51 | 17.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Nov 21, 2022.
Who owns Zoetis Inc.
Ownership data of Zoetis Inc. is not available yet.
Zoetis Inc. company profile
- Company name
- Zoetis Inc.
- Ticker
- Z1TS34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 14,500
- Fiscal year end
- December
- Address
- 10 Sylvan Way, Parsippany, NJ, United States, 07054
- Phone
- 973 822 7000
- Website
- zoetis.com
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Zoetis Inc. management
10- Ms. Kristin C. PeckCEO & Director · born 1971
- Ms. Roxanne LaganoExecutive VP, General Counsel & Corporate Secretary · born 1965
- Mr. Wetteny N. Joseph CPASpecial Advisor to the CEO · born 1972
- Dr. Robert J. Polzer Ph.D.Scientific Advisor · born 1969
- Mr. Jamie BrannanExecutive VP & Chief Commercial Officer · born 1973
- Mr. James K. SaccaroExecutive VP, CFO & COO · born 1973
- Mr. Keith SarbaughExecutive VP & Chief Digital and Technology Officer · born 1979
- Mr. Steven FrankVice President of Investor Relations
- Ms. Julie A. FullerExecutive VP, Chief Human Resources Officer & Global Operations · born 1973
- Mr. Abhay U. NayakExecutive VP & President of U.S. Commercial Operations · born 1988